Loading...
Market
Most Common Public Health Response to Myocarditis Study Findings by End of 2024
2
Resolution / Starting Odds
Increased monitoring • 25%
Policy revision • 25%
Public reassurance • 25%
No action taken • 25%
Public health announcements, policy papers, or press releases
Story
Study of 1.7 Million Children Finds Myocarditis Only in COVID-19 Vaccinated
Oct 9, 2024, 12:00 PM
A recent study involving 1.7 million children found that myocarditis and pericarditis occurred exclusively in those who received COVID-19 vaccines. The study indicated zero cases of these conditions among unvaccinated children. This finding has sparked significant concern and debate about the safety of COVID-19 vaccines for children. Additionally, there have been reports of heart damage in vaccinated children, with no such cases in the control group, including a rate of 37 per million. A few months into the rollout, a previously healthy 15-year-old developed myocarditis weeks after receiving the injection.
View original story
Similar markets
Update vaccination guidelines • 25%
Initiate new studies • 25%
Issue a public warning • 25%
No significant action • 25%
Stricter age limits for vaccination • 25%
Increased monitoring and reporting • 25%
Incentives for alternative vaccines • 25%
No change in policy • 25%
Increase in vaccination age limits • 25%
Introduction of additional health screenings • 25%
No change in current policies • 25%
Other policy changes • 25%
Acknowledge and propose further studies • 25%
Deny correlation and defend vaccine safety • 25%
Announce new vaccine formulations • 25%
No official response • 25%
Closure of Khushi Juice Corner • 25%
Fines imposed • 25%
New regulations on juice vendors • 25%
No action taken • 25%
Persistent viral RNA • 25%
T cell activation • 25%
Chronic inflammation • 25%
Other • 25%
Implement moratorium • 25%
Conduct further research • 25%
Ignore findings • 25%
Issue public warnings • 25%
Class action lawsuits settled • 25%
Individual lawsuits successful • 25%
No successful lawsuits • 25%
Ongoing litigation • 25%
Increased oversight on research funding • 25%
Reevaluation of pandemic response strategies • 25%
Improved fraud prevention measures • 25%
Public communication and trust-building • 25%
Increased funding for research • 25%
New public health campaigns • 25%
No significant changes • 25%
New regulations or policies • 25%
Vaccination • 25%
Changes in the virus • 25%
Improved treatments • 25%
Other factors • 25%
Increased vaccine hesitancy • 25%
No significant change • 25%
Increased trust in vaccines • 25%
Public divided • 25%